1. Academic Validation
  2. Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta

Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta

  • J Med Chem. 2009 Feb 12;52(3):858-67. doi: 10.1021/jm801458t.
Filippo Minutolo 1 Simone Bertini Carlotta Granchi Teresa Marchitiello Giovanni Prota Simona Rapposelli Tiziano Tuccinardi Adriano Martinelli Jillian R Gunther Kathryn E Carlson John A Katzenellenbogen Marco Macchia
Affiliations

Affiliation

  • 1 Dipartimento di Scienze Farmaceutiche, Universita di Pisa, Via Bonanno 6, 56126 Pisa, Italy. minutolo@farm.unipi.it
Abstract

The bioisosteric replacement of the phenol ring, a signature functional group of most Estrogen Receptor (ER) ligands, with a hydrogen-bonded pseudocyclic ring, led to the development of a novel class of nonsteroidal ER-ligands based on a salicylaldoxime template. A series of structural modifications were applied to selected molecules belonging to the monoaryl-salicylaldoxime chemical class in an attempt to improve further their ERbeta-selective receptor affinity and agonist properties. Among several modifications, the best results were obtained by the simultaneous introduction of a meta-fluorine atom into the para-hydroxyphenyl substituent present in the 4-position of salicylaldoxime, together with the insertion of a chloro group in the 3-position of the central scaffold. The resulting compound showed the best affinity (K(i) = 7.1 nM) and selectivity for ERbeta over ERalpha. Moreover, in transcription assays, it proved to be a selective and potent ERbeta-full agonist with an EC(50) of 4.8 nM.

Figures
Products